Pages that link to "Q28259350"
Jump to navigation
Jump to search
The following pages link to MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma (Q28259350):
Displaying 14 items.
- High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time (Q28536347) (← links)
- Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. (Q34023497) (← links)
- Monoclonal antibodies in gynecological cancer: a critical point of view (Q35659915) (← links)
- MUC1 drives c-Met-dependent migration and scattering. (Q36484469) (← links)
- The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. (Q36544576) (← links)
- Massive transcranial parotid pleomorphic adenoma: recurrence after 30 years (Q36857911) (← links)
- Vaccine-based clinical trials in ovarian cancer (Q37892583) (← links)
- Monoclonal antibodies therapies for ovarian cancer (Q38078400) (← links)
- The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. (Q38100999) (← links)
- Therapeutic vaccines for ovarian cancer (Q38117024) (← links)
- Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases (Q38560347) (← links)
- Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. (Q39063057) (← links)
- Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance (Q79972618) (← links)
- Pre-clinical safety evaluation of heat shock protein 65-MUC1 peptide fusion protein (Q80546286) (← links)